Results 111 to 120 of about 333,288 (246)

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited. Objectives To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy ...
Mario Hero, Nadja Grozdanić, Romana Brnić Andrić, Eliša Papić, Olivio Perković, Vladimira Vuletić   +5 more
wiley   +1 more source

Concomitant activation of D1 dopamine and α2A adrenergic receptors improves cognition better than methylphenidate in two rodent behavioral tests

Discover Pharmaceutical Sciences
Rationale Methylphenidate is commonly prescribed to manage symptoms of attention-deficit/hyperactivity disorder (ADHD), but like other stimulants it has variable effectiveness. Methylphenidate works by increasing the synaptic availability of dopamine and
Luke Bransom, Ava P. Bassett, Mi Zhou, Richard B. Mailman, Yang Yang   +4 more
doaj   +1 more source

Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature

Endocrine Journal
Amyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tumour burden and markedly elevated ...
Aysel Unver Ozkahraman, Merve Korkmaz Yilmaz, Huseyin Karatay, Sidar Bagbudar, Ebubekir Akpinar, Buruc Erkan, Mehmet Karagulle, Mesut Yilmaz, Mutlu Niyazoglu, Esra Hatipoglu   +9 more
doaj   +1 more source

Continuous Subcutaneous Apomorphine as a Temporary Bridging Therapy for Dopamine Dysregulation Syndrome in Patients with Deep Brain Stimulation

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a challenging complication of dopaminergic therapy in Parkinson's disease and can persist despite subthalamic deep brain stimulation (STN‐DBS). We evaluated a temporary bridging concept in which oral dopaminergic medication was replaced by continuous subcutaneous apomorphine infusion while ...
Tobias Binder, Johannes Hartig, Lennart Sitzmann, Chi Wang Ip, Philipp Capetian, Florian Lange, Martin Reich, Christine Daniels, Jens Volkmann   +8 more
wiley   +1 more source

THE D2 DOPAMINE RECEPTOR AGONIST LY171555 INDUCES CATALEPSY IN THE MOUSE

, 1988
The dopamine agonist LY171555 (quinpirole), a specific D2 receptor agonist, induces catalepsy in mice at doses ranging from 0.3 to 10 mg/kg. The effects of an intermediate dose of this compound (1 mg/kg SC) were antagonized by 25 mg/kg of the selective ...
CABIB, Simona, PUGLISI ALLEGRA, Stefano
core   +1 more source

Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion

Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Only PD-SDB patients treated with a dopamine agonist (DA+) showed a significant decrease of SDB severity during REM sleep.

, 2014
Only PD-SDB patients treated with a dopamine agonist (DA+) showed a significant decrease of SDB severity during REM sleep.
Esther Werth (121363), Michael Sommerauer (589115), Sabrina Hauser (397435), Philipp O. Valko (589114), Christian R. Baumann (121378)   +4 more
core   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source